Closing Bell Recap: Surgery Partners Inc (SGRY) Ends at $20.39, Reflecting a -3.59% Downturn

Abby Carey

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

Surgery Partners Inc (NASDAQ: SGRY) closed the day trading at $20.39 down -3.59% from the previous closing price of $21.15. In other words, the price has decreased by -$3.59 from its previous closing price. On the day, 1.5 million shares were traded. SGRY stock price reached its highest trading level at $21.19 during the session, while it also had its lowest trading level at $20.36.

Ratios:

For a better understanding of SGRY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.91. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.93. In the meantime, Its Debt-to-Equity ratio is 2.22 whereas as Long-Term Debt/Eq ratio is at 2.13.

On December 16, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $30.BofA Securities initiated its Buy rating on December 16, 2024, with a $30 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 29 ’25 when Wayne DeVeydt bought 18,134 shares for $22.05 per share.

Wayne DeVeydt bought 5,627 shares of SGRY for $123,794 on Sep 26 ’25. On Sep 23 ’25, another insider, Wayne DeVeydt, who serves as the former director of the company, bought 25,000 shares for $22.02 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 2614189824 and an Enterprise Value of 8068407296. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.81 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 2.493 whereas that against EBITDA is 12.511.

Stock Price History:

The Beta on a monthly basis for SGRY is 1.86, which has changed by -0.31044978 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, SGRY has reached a high of $33.37, while it has fallen to a 52-week low of $18.87. The 50-Day Moving Average of the stock is -8.40%, while the 200-Day Moving Average is calculated to be -9.73%.

Shares Statistics:

Over the past 3-months, SGRY traded about 1.46M shares per day on average, while over the past 10 days, SGRY traded about 1219810 shares per day. A total of 128.21M shares are outstanding, with a floating share count of 75.98M. Insiders hold about 40.74% of the company’s shares, while institutions hold 73.79% stake in the company. Shares short for SGRY as of 1757894400 were 13218704 with a Short Ratio of 9.04, compared to 1755216000 on 12747748. Therefore, it implies a Short% of Shares Outstanding of 13218704 and a Short% of Float of 21.86.

Earnings Estimates

The market rating for Surgery Partners Inc (SGRY) is a result of the insights provided by 11.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.47, with high estimates of $0.61 and low estimates of $0.32.

Analysts are recommending an EPS of between $1.06 and $0.57 for the fiscal current year, implying an average EPS of $0.85. EPS for the following year is $1.01, with 11.0 analysts recommending between $1.65 and $0.69.

Revenue Estimates

11 analysts predict $823.55M in revenue for. The current quarter. It ranges from a high estimate of $839.4M to a low estimate of $803.8M. As of. The current estimate, Surgery Partners Inc’s year-ago sales were $770.4MFor the next quarter, 11 analysts are estimating revenue of $931.12M. There is a high estimate of $951.2M for the next quarter, whereas the lowest estimate is $904.35M.

A total of 11 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.39B, while the lowest revenue estimate was $3.32B, resulting in an average revenue estimate of $3.36B. In the same quarter a year ago, actual revenue was $3.11BBased on 11 analysts’ estimates, the company’s revenue will be $3.68B in the next fiscal year. The high estimate is $3.77B and the low estimate is $3.62B.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.